文献速递肺外科

肺神经内分泌肿瘤TNM分期改进需结合组织学与肿瘤大小重分组

Improvement in TNM staging of pulmonary neuroendocrine tumors requires histology and regrouping of tumor size.
PubMed 文献 · J Thorac Cardiovasc Surg · 2017-09-09

该研究回顾性分析8中心510例肺神经内分泌肿瘤手术患者,提出结合组织学分级与pT重分组的新分期系统,其5年生存率各期区分度优于第7版TNM。

要点

  • 组织学分级与pT是独立预后因素,pN不是。
  • 新分期将G1-G3与pT1-4组合为IA-III期。
  • 新分期各期5年生存率梯度更清晰。

核心结论

  • 结合组织学与肿瘤大小重分组的新分期系统对生存的预测优于第7版TNM。

研究设计与样本

  • 回顾性分析8中心2000-2015年510例连续肺神经内分泌肿瘤手术患者,中位年龄61岁。
  • 采用Cox比例风险模型进行多因素分析,Kaplan-Meier法分析疾病特异性生存。

主要发现

  • 组织学(G1典型类癌 vs G2非典型类癌 vs G3大细胞神经内分泌癌)和pT与生存独立相关,pN不独立相关。
  • 新分期IA、IB、IIA、IIB、III期的5年生存率分别为97.9%、81.0%、69.1%、51.8%、0%。
  • 第7版TNM IA、IB、IIA、IIB、III期的5年生存率分别为95.0%、92.3%、67.7%、70.9%、65.1%。

关键数值与推荐

  • 新分期:IA(pT1-2G1),IB(pT3G1,pT1G2),IIA(pT4G1,pT2-3G2,pT1G3),IIB(pT4G2,pT2-3G3),III(pT4G3)。

临床怎么用

  • 肺神经内分泌肿瘤分期应纳入组织学分级并据此重分组肿瘤大小,以更准确预测生存。

局限性

  • 回顾性研究,随访510例中完成490例,中位随访51个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Neuroendocrine tumors of the lung are currently staged with the 7th edition TNM non-small cell lung cancer staging system. This decision, based on data analysis without data on histology or disease-specific survival, makes its applicability limited. This study proposes a specific staging system for these tumors. METHODS: We retrospectively analyzed 510 consecutive patients (female/male, 313/197; median age, 61 years; interquartile range, 51-70) undergoing lung resection for a primary neuroendocrine tumor between 2000 and 2015 in 8 centers. Multivariable analysis was performed using a Cox proportional hazard model to identify factors associated with disease-specific survival. A new staging system was proposed on the basis of the results of this analysis. Kaplan-Meier disease-specific survival was analyzed by stage using the proposed and the 7th TNM staging system. RESULTS: Follow-up was completed in 490 of 510 patients at a median of 51 months (interquartile range, 18-99). Histology (G1-typical carcinoid vs G2-atypical carcinoid vs G3-large-cell neuroendocrine carcinoma) and pT were independently associated with survival, but pN was not. After regrouping histology and pT, we proposed the following staging system: IA (pT1-2G1), IB (pT3G1, pT1G2), IIA (pT4G1, pT2-3G2, pT1G3), IIB (pT4G2, pT2-3G3), and III (pT4G3). The 5-year survivals were 97.9%, 81.0%, 69.1%, 51.8%, and 0%, respectively. By using the 7th TNM, 5-year survivals were 95.0%, 92.3%, 67.7%, 70.9%, and 65.1% for stage IA, IB, IIA, IIB, and III, respectively. CONCLUSIONS: Incorporating histology and regrouping tumor stage create a unique neuroendocrine tumor staging system that seems to predict survival better than the 7th TNM classification.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Cattoni M, Vallières E, Brown LM, et al. Improvement in TNM staging of pulmonary neuroendocrine tumors requires histology and regrouping of tumor size. J Thorac Cardiovasc Surg. 2017. PMID: 28986041. doi:10.1016/j.jtcvs.2017.08.102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。